Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Leerink Partners Downgrades Tesaro (TSRO) to Market Perform
February 10, 2017 6:51 AM ESTLeerink Partners downgraded Tesaro (NASDAQ: TSRO) from Outperform to Market Perform with a price target of $186.00 (from $152.00).
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $186.91 yesterday.
... MoreTESARO (TSRO) may be worth $250/share in sale, Bloomberg citing SunTrust
February 8, 2017 1:07 PM ESTTESARO (NASDAQ: TSRO) may be worth $250/share in sale, Bloomberg citing SunTrust.
... More


